Biotechnology News

Discover the latest in biotechnology with press releases highlighting innovations, research, and developments driving biotech's future. Stay informed on advancements changing biotech and explore opportunities in genetic engineering, pharmaceuticals, and bioengineering.

Feb 3, 2026 at 9:57 PM

Veradermics Announces Pricing of Upsized Initial Public Offering

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the shares are being offered by Veradermics. The gross proceeds fro...
Feb 3, 2026 at 4:05 PM

Simulations Plus to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that Shawn O’Connor, Chief Executive Officer, will be participating in the upcoming investor conferences: BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Format: One-on-one meetings When: Tuesday, February 10, 2026 Location...
Feb 3, 2026 at 4:05 PM

Rallybio Announces Reverse Stock Split of Common Stock

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an amendment to Rallybio’s Amended and Restated Certificate of Incorporation (the “Amendment”) to effect the reverse stock split at a Special Meeting of Stockholders held on January 26, 2026. The reverse stock split is intended to give Rallybio greater flexibility in considering and planning for futur...
Feb 3, 2026 at 4:05 PM

QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN’s entry into high-throughput benchtop automation for sample processing in research laboratories. QIAsprint Connect is designed to help labs process large batches of samples efficiently while retaining control over protocols and reducing environmental footprint. The compact system suppo...
Feb 3, 2026 at 4:01 PM

Transcat Reports Strong Fiscal Third Quarter 2026 Financial Results with a Return to High Single-Digit Service Organic Revenue Growth*

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Reports Strong Fiscal Third Quarter 2026 Financial Results with a Return to High Single-Digit Service Organic Revenue Growth*...
Feb 3, 2026 at 3:28 PM

Nucleai Enables Spatial Biology Research in Nature Communications Study on Lung Cancer Treatment Response

TEL AVIV, Israel--(BUSINESS WIRE)--Nucleai, a leader in AI-powered multimodal spatial biology, today announced its contribution to a collaborative international study published in Nature Communications that explores how spatial organization and metabolic characteristics of tumor cells are associated with response and resistance to immunotherapy in non-small cell lung cancer (NSCLC). The study, led by academic researchers at The University of Queensland and Yale School of Medicine, applied multi...
Feb 3, 2026 at 11:00 AM

AGC Biologics Seattle Site Now Certified to Manufacture Biologics for Largest Pharmaceutical Market in South America

SEATTLE--(BUSINESS WIRE)--The Seattle facility of AGC Biologics received GMP Certification from Anvisa (Brazil), extending the global reach of AGC Biologics’ customers....
Feb 3, 2026 at 10:02 AM

Southern Research, Pathogenus Create Global Partnership

BIRMINGHAM, Ala.--(BUSINESS WIRE)--Southern Research and London-based Pathogenus Consulting have signed a three-year partnership that will allow both organizations to capitalize on growing research opportunities around the world. "We’ve seen clear momentum in our work with partners outside the United States, especially with Japan and European pharmaceutical companies, and the opportunity to broaden that footprint is both exciting and timely,” said Fusataka Koide, senior director of global clien...
Feb 3, 2026 at 10:00 AM

Lōkahi Therapeutics Welcomes the Student Industry Fellows Program at the University of Georgia to the ai² Futures Lab™ Program

LA JOLLA, Calif. & ATHENS, Ga.--(BUSINESS WIRE)--Lōkahi Therapeutics today announced the participation of the University of Georgia’s Student Industry Fellows Program in its ai² (actual intelligence) Futures Lab program for the Spring 2026 semester. Through this collaboration, University of Georgia students will engage in applied, real-world biotech and life sciences projects designed to bridge academic learning with industry execution. The ai² Futures Lab program pairs multidisciplinary studen...
Feb 3, 2026 at 9:54 AM

CareDx to Present AlloHeme™ Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that pivotal clinical validation data from the ACROBAT study (NCT04635384) will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®,...
Turn Your News Into Headlines
Submit Your Release

Get Story Ideas Delivered to Your Inbox

Sign Up